Search Result

Results for "

tau pathology

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Tau Protein (5) Amyloid-β (2) ATTECs (1) Autophagy (3) Calcium Channel (1) Ferroptosis (2) Interleukin Related (1) MyD88 (1) NOD-like Receptor (NLR) (2) Reference Standards (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (3) Inflammation/Immunology (2) Neurological Disease (8)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Inhibitory Antibodies

Targets Recommended: Tau Protein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103157

PD146176 5 Publications Verification NSC168807	Autophagy Ferroptosis	Cardiovascular Disease
PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (K_i=197 nM, IC₅₀=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .

HY-101183

THK5351	Tau Protein	Neurological Disease
THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of *tau* pathology in the brain.

HY-162566

REM127	Calcium Channel Amyloid-β	Neurological Disease
REM127 is a small molecule compound capable of modulating calcium homeostasis in cells and possesses neuroprotective effects. REM127 can restore the calcium homeostasis imbalance in cellular models caused by pathological accumulation of tau protein. REM127 can efficiently cross the blood-brain barrier, and it has the potential to rescue synaptic and cognitive deficits in Alzheimer's disease animal models, as well as to slow down the progression of amyloid-beta and tau protein pathologies. REM127 can be used for research in neurodegenerative diseases .

HY-P99555

Tomaralimab OPN-305	Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) Tau Protein Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces *tau* pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .

HY-100723

THK-523	Amyloid-β	Neurological Disease
THK-523 has demonstrated its high affinity and selectivity for *tau* pathology both in vitro and in vivo. ¹⁸F-THK523 is a potent tau imaging radiotracer. ¹⁸F-THK523 is a potent in vivo tau imaging ligand for Alzheimer's disease .

HY-103157R

PD146176 (Standard) NSC168807 (Standard)	Reference Standards Autophagy Ferroptosis	Cardiovascular Disease
PD146176 (Standard) is the analytical standard of PD146176. This product is intended for research and analytical applications. PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (Ki=197 nM, IC50=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .

HY-176130

MRL828	ATTECs Tau Protein Autophagy	Neurological Disease
MRL828 combines a Tau pathology-binding ligand and modified guanine moiety based on the ATTEC technology to selectively designate aggregated tau proteins for clearance via the ALP. MRL828 decreases intracellular *Tau* aggregates and promotes the secretion of Tau .

HY-W338446

BF-170	Tau Protein	Neurological Disease
BF-170 is a selective *tau* fibril binding agent with an EC₅₀ of 221 nM. It exhibits good blood-brain barrier permeability, and after intravenous injection in mice, the concentration in brain tissue reaches 9.1% ID/g within 2 minutes (with a brain clearance rate of 0.25% ID/g after 30 minutes). BF-170 can be used as a probe for *tau* protein pathology imaging in Alzheimer's disease (AD). It plays an important role in early-stage AD research and holds potential for imaging studies of tau-related neurodegenerative diseases .

HY-162020

SB1617	Tau Protein	Neurological Disease Inflammation/Immunology
SB1617 is a neuroinflammation-modulating agent, and has neuroprotective effect by reducing pathogenic tau levels through microglia-mediated anti-inflammatory activity .

HY-172941

VEN-02XX	NOD-like Receptor (NLR)	Neurological Disease
VEN-02XX is an orally active and brain-permeable NLRP3 inhibitor. VEN-02XX inhibits the release of IL-1β and IL-18 (IC₅₀ 0.3 and 0.28 μM, respectively). VEN-02XX restores memory and cognition, inhibits microgliosis, and reduces neuroinflammation and tau pathology in the 5XFAD/Rubicon KO mouse model. VEN-02XX may be used in the study of Alzheimer's disease (AD) .

Cat. No.	Product Name

HY-L069

Anti-Alzheimer's Disease Compound Library	1,734 compounds
Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc. MCE offers a unique collection of 1,734 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

Anti-Alzheimer's Disease Compound Library

1,734 compounds

Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc.

MCE offers a unique collection of 1,734 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

Cat. No.	Product Name	Type

HY-101183

THK5351	Indicators
THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of *tau* pathology in the brain.

Cat. No.	Product Name	Target	Research Area

HY-P99555

Tomaralimab OPN-305	Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) Tau Protein Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces *tau* pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.